Payers, Providers, and Patients
What is the Health Insurers’ Role?
Health insurers, both leading insurance companies as well as self-insured employers, are crucial in order to ensure there is coverage for whole genome sequencing and proteomic testing. They will ensure medical policy is in place to support patients having access to this leading edge science, the trials, and the subsequent care by providing coverage and valuable data. Independence Blue Cross, under the helm of CEO Daniel Hilferty, was the first leading payer to announce coverage for GPS Cancer, and we are seeing many self-insured employers beginning to offer coverage and significant traction with other payers as well.
What is the Provider’s Role?
Both academic cancer centers and community oncologists will enroll and provide treatments to the 20,000 patients who will participate in these multiple cancer trials across multiple tumor types including breast, lung, prostate, ovarian, brain, head and neck, multiple myeloma, and up to 20 additional tumor types.
The Cancer MoonShot 2020 network currently brings together nearly 1,000 oncologists across the United States-at academic medical centers and community hospital and ambulatory settings – who believe in the power of genomics and proteomics technologies and want to drive discovery of new therapies through clinical trials. The Cancer MoonShot 2020 network also extends worldwide and is generating much interest from oncologists in the UK, Europe, Israel and Singapore.
How can Patients Participate?
Please speak with your oncologist. If your oncologist is not familiar with Cancer MoonShot 2020, you can direct him or her to www.cancermoonshot2020.org for more information. NantHealth’s Nant Care Center can provide you with information on participating PMGN physicians, and you can follow us on Twitter @moonshot2020 for breaking program updates.